Literature DB >> 15570250

Graft-versus-host disease: how to translate new insights into new therapeutic strategies.

Marcel P Devetten1, Julie M Vose.   

Abstract

Graft-versus-host disease occurs when transplanted donor-derived T lymphocytes recognize major or minor histocompatibility complex proteins and their associated peptides expressed by recipient antigen-presenting cells. A widely accepted paradigm for the pathophysiology of acute GVHD is based on the existence of 3 sequential steps: (1) injury to the host environment (as would occur during conditioning regimens); (2) donor T-cell activation, proliferation, and differentiation; and (3) damage to the target tissue caused by either cytotoxicity or indirectly by inflammatory cytokines. In order to reduce the incidence of GVHD, recent studies have focused on methods of prophylaxis as well as novel treatments for established GVHD. We review each phase in the development of acute GVHD and discuss recently developed interventions aimed to prevent or treat GVHD by interfering with these pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15570250     DOI: 10.1016/j.bbmt.2004.10.005

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  6 in total

1.  Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells.

Authors:  Rafet Basar; May Daher; Nadima Uprety; Elif Gokdemir; Abdullah Alsuliman; Emily Ensley; Gonca Ozcan; Mayela Mendt; Mayra Hernandez Sanabria; Lucila Nassif Kerbauy; Ana Karen Nunez Cortes; Li Li; Pinaki P Banerjee; Luis Muniz-Feliciano; Sunil Acharya; Natalie W Fowlkes; Junjun Lu; Sufang Li; Stephan Mielke; Mecit Kaplan; Vandana Nandivada; Mustafa Bdaiwi; Alexander D Kontoyiannis; Ye Li; Enli Liu; Sonny Ang; David Marin; Lorenzo Brunetti; Michael C Gundry; Rolf Turk; Mollie S Schubert; Garrett R Rettig; Matthew S McNeill; Gavin Kurgan; Mark A Behlke; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Blood Adv       Date:  2020-07-28

Review 2.  Graft-versus-host disease and immunosuppression.

Authors:  Neena Kapoor
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  Critical role of DNAX accessory molecule-1 (DNAM-1) in the development of acute graft-versus-host disease in mice.

Authors:  Tsukasa Nabekura; Kazuko Shibuya; Eri Takenaka; Hirayasu Kai; Kai Shibata; Yumi Yamashita; Kyoichi Harada; Satoko Tahara-Hanaoka; Shin-ichiro Honda; Akira Shibuya
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

4.  Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease.

Authors:  Akiyoshi Takami; Kanako Mochizuki; Hirokazu Okumura; Satsuki Ito; Yukio Suga; Hirohito Yamazaki; Masahide Yamazaki; Yukio Kondo; Hidesaku Asakura; Shinji Nakao
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

5.  TNF, LTA and TGFB1 genotype distributions among acute graft-vs-host disease subsets after HLA-matched unrelated hematopoietic stem cell transplantation: a pilot study.

Authors:  R Shah; S T Selby; B Yokley; R S Slack; C K Hurley; P E Posch
Journal:  Tissue Antigens       Date:  2009-04-08

6.  The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics.

Authors:  Marina G M Castor; Vanessa Pinho; Mauro M Teixeira
Journal:  Front Pharmacol       Date:  2012-02-24       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.